The Effectiveness of Using E-Cigarettes for Smoking Cessation and Decreasing Risk of Diseases Among Heavy Smokers
NCT ID: NCT05639790
Last Updated: 2023-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2023-11-01
2024-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is there any effectiveness of using E-cigarette as a harm reduction strategy for smoking cessation?
* what are the impacts of using E-cigarette on respiratory function and risk of COPD?
* Assess the exposure to harmful and potential harmful constituents (HPHCs) of using E-cigarette
Participants will be randomized into a 6 months single-center, open label trial comparing study outcomes among 2 arms: health counselling, E-cigarette + health counselling. The EC arm will receive EC for 1 month. All 2 arms will receive health counselling from a licensed mental health counselor. After baseline, participants will report their use of combustible cigarette in both arms and EC use in the EC arm every day via online questionnaire in Wechat for behavioral monitoring.
If there is a comparison group: Researchers will compare health counselling group to see if E-cigarrette intervention is an effective way to stop smoking, and if there any change in respiratory function and change in exposure to harmful and potential harmful constituents (HPHCs).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Different THR Products in Adult Population
NCT05825924
e-Cigarettes Versus NRT Gum for Smoking Cessation
NCT01925781
Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT
NCT06088862
Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
NCT04210180
Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
NCT00710034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Counselling
Health counselling from a licensed mental health counselor
Health Counselling
Health Counselling from a licensed mental health counselor
Eletronic cigarette
Ad libitum use of electronic cigarettes for 1 month and health counselling from a licensed mental health counselor
Electronic cigarettes + Health Counselling
Ad libitum use of electronic cigarettes for 1 month
Health Counselling
Health Counselling from a licensed mental health counselor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electronic cigarettes + Health Counselling
Ad libitum use of electronic cigarettes for 1 month
Health Counselling
Health Counselling from a licensed mental health counselor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The nicotine dependence test (FNDT) result score is 6-10 points
* Self-reported smoking at least 10 cigarettes a day, and smoking for at least 3 years
* Self-reported no current willingness to quit smoking
* Self-reported difficulty controlling the need to smoke, or smoking while sick in bed
* Must not accepted smoking cessation treatment in the last 3 months according to the self-report
* Must have never tried e-cigarette before
* Must be able to fully understand the purpose, nature and content of the research, and voluntarily sign the informed consent form as a subject
* Must agree and able to communicate well with the researcher, and able to complete the online questionnaire and examination in accordance with the research regulations.
Exclusion Criteria
* Severe disease (defined as an illness or condition that put the patient at risk, interfere the trial results, or affect the patient's ability to participate in the trial judged by the panel)
* Past diagnosis of COPD, lung cancer, pneumoconiosis, bronchiectasis, interstitial lung disease, bronchial asthma, or other restrictive ventilatory disorder
* Living with severe heart, brain, liver, kidney, blood system diseases or malignant tumors
* Moderate-severe renal impairment, or creatinine clearance (CCr) ≤50ml/min
* Phenylpyruvaturia
* Allergic predisposition (be allergic to two or more substances), and is allergic to any of the components in e-cigarettes or e-liquid (e.g., benzoic acid, propylene glycol, glycerin, nicotine, etc.)
* Already been enrolled into a smoking cessation treatment, including but not limited to nicotine replacement therapy (NRT), varenicline, bupropion
* Living with mental illness, a history of chronic alcoholism, drug abuse, or any factor that affects compliance
* Participating in other clinical trials
* Life-threatening condition with a life expectancy less than 1 year
* Researcher believes that it is not suitable to participate in this researcher.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen Smoore Technology Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SR20221001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.